Onco IX (PHC-102, Imaging)

Onco IX (PHC-102) is a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors.
The product consists of (i) an acetazolamide ligand derivative specific to CAIX, (ii) a non-cleavable spacer and (iii) a peptide chelator.


CAIX is a validated target, which is not only expressed in the vast majority of Renal Cell Carcinoma (RCC), but also in other hypoxic tumors (e.g.,  a proportion of Colorectal Carcinoma and High-Grade Glioma).
In preclinical studies, Onco IX has demonstrated a high tumor uptake and favourable tumor-to-organ ratios.
The in vivo targeting properties of Onco IX have been validated both in preclinical models and in human patients with advanced RCC tumors.


Kulterer et al. (2021) J Nucl Med, 62, 360-5

Cazzamalli et al. (2018) Clin Cancer Res, 24, 3656-67

Cazzamalli et al. (2018) JACS, 140, 1617-21

Cazzamalli et al. (2017) J Control Release, 246, 39-45

Cazzamalli et al. (2016) Mol Cancer Ther, 15, 2926-35

Krall et al. (2016) J Nucl Med, 57, 943-9

Wichert et al. (2015) Nat Chem, 7, 241-9

Krall et al. (2014) Chem Sci, 5, 3640-4

Krall et al. (2014) Angew Chem Int Ed, 53, 4231-5